



Development of Therapeutic Antibodies and Their Antigens for Treatment of Disease

Guest Editors:

Dr. Jung-Hyun Na

Department of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea

Dr. Tae Hyun Kang

Department of Biopharmaceutical Chemistry, Kookmin University, 77 Jeongneung-ro, Seongbuk-gu, Seoul 02707, Korea

Deadline for manuscript submissions:

closed (15 July 2023)

Message from the Guest Editors

Dear Colleagues,

Therapeutic antibodies have become the prevailing class of novel therapeutic drug candidates in recent years, due to their high specificity and fewer adverse effects. As a result, new antibody drugs have been developed to treat various human diseases, including cancers, infectious diseases, and autoimmune diseases, which has led to unprecedented growth in the pharmaceutical market.

This Special Issue covers the development of antibody drugs (or candidates), the latest advances in the discovery, engineering, validation, and manufacturing of therapeutic antibodies, and novel antibody-based therapeutic platforms, including bispecific-antibodies, single-domain antibodies, and antibody–drug conjugates. This Special Issue invites both original research and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)